What are the purchasing channels for Nadimedin?

Symproic (naldemedin) is a drug used to treat opioid-induced constipation (OIC) in adults with chronic non-cancer pain. Since it has not yet been launched in China and is not covered by medical insurance, patients need to purchase it through specific channels. This article will introduce in detail the purchase channels, listing status and price information of nadimedine to help patients and their families better understand how to obtain this drug.

What are the purchasing channels for Nadimedine?

Currently it is not available in China. Patients need to obtain it through other formal channels. The following are several common purchasing channels.

Cross-border e-commerce platform

Cross-border e-commerce platform provides patients with a convenient way to purchase Nadimedine. Patients can place orders directly through the platform, but they must choose a reputable merchant and carefully check the production date, specifications and packaging integrity of the drug to avoid purchasing fake or inferior drugs.

Regular medical service institutions

Some international medical service institutions cooperate with overseas pharmacies to provide patients with purchasing services for Nadimedin. Patients can obtain medicines through these institutions and also receive professional medication guidance.

Overseas direct mail

Patients can also directly mail Nadimedine from Japan or other listed countries through overseas relatives and friends. During the mailing process, attention should be paid to the storage conditions of the medicine to ensure that the medicine is not damaged during transportation.

No matter which channel they purchase, patients should choose carefully to ensure the authenticity of the medicine.

The listing status of Nadimedine

The listing status of Nadimedine has an important impact on the purchase and use of patients. The following is a detailed introduction to its listing information.

International marketing status

Nadimedine was developed by Amgen of the United States and was approved for marketing in Japan on March 23, 2017. It is currently available in many countries and regions, but has not yet been approved in China.

Reasons for not being listed in China

Due to factors such as the approval process and market demand, Nadimedine has not yet been listed in China. Patients need to obtain drugs through other channels, and there are currently no generic drugs available in China.

Future marketing prospects

With the increasing demand for the treatment of constipation caused by opioids, Nadimedine may apply for marketing in China in the future. Patients can follow relevant developments and obtain the latest information in a timely manner.

Understanding the marketing status of Nadimedine can help patients make a reasonable drug purchase plan.

The price of Nadimedine

The price of Nadimedin varies depending on specifications and purchase channels. The following is a detailed analysis of its price.

Price of Japan's Shionogi Pharmaceutical

Nadimedine produced by Japan's Shionogi Pharmaceutical has two specifications. The price of 0.2mg*50 tablets/box is US$520, and the price of 0.2mg*14 tablets/box is US$173. The price is relatively high, but the quality of the medicines is guaranteed.

Price difference

When purchased through cross-border e-commerce or medical service institutions, the price may increase due to factors such as transportation costs and tariffs. Patients need to understand the cost details in advance to avoid additional expenses.

Price is an important reference factor for patients when choosing purchasing channels, and reasonable planning can help reduce the financial burden.